Treg Cell And PD-1 In Cancer Immunotherapy

Haomin Feng; Jiayue Wang; Ruibo Yu

doi:10.54097/hset.v45i.7484

Authors

Haomin Feng
Jiayue Wang
Ruibo Yu

DOI:

https://doi.org/10.54097/hset.v45i.7484

Keywords:

Treg Cell; PD-1; Cancer; Immunotherapy.

Abstract

Cancer results from the abnormal life activity of some cells in the human body. These abnormal life activities are mainly reflected in uncontrolled division and proliferation and can infiltrate and destroy normal human tissues. In actuality, more than a million people die from cancer annually, and it ranks first among the main causes of death globally. Common cancers include skin cancer, lung cancer, gastric cancer, pancreatic cancer, etc. In the modern era, immunotherapy is the mainstay of treatment for some relatively common cancers, such as breast and prostate cancer. There are many ways to treat cancer in the world. In this article, the author only compares two possible ways to treat cancer: Treg cell method and PD-1 therapy. This paper tried to clarify the advantages and disadvantages of these two immunotherapies in cancer treatment by studying and comparing the two immunotherapies for cancer treatment, to help researchers find better ways to treat cancer with immunotherapy.

Downloads

Download data is not yet available.

References

Cancer statistics based on combined data from England, Scotland, Northern Ireland and Wales. World Cancer Research Fund, 2022. https://www.wcrf-uk.org/preventing-cancer/uk-cancer-statistics/.

Foldvari M, Chen DW, Nafissi N, et al. non-viral gene therapy: gains and challenges of non-invasive administration methods. J Control Release. 2016; 240:165-190.

Gholami A, Roshanfard F, Ghasemi Y. A comprehensive review of gene therapy, recent progress and future prospects. Razi J Med Sci. 2016;23(149):28-45.

Foss FM.DAB (389) IL-2 (ONTAK): a novel fusion toxin therapy for lymohoma [J]. Clini Lymohoma. 2000,1(2):110-116.

Goubran, Hadi A. et al. “Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment.” Cancer Growth and Metastasis 2014.2014 (2014): 9–18.

Saouaf SJ, Sananta A, Shen Y, et al. Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity immune suppression [J], CurrOpin Immunol 2007.19(5):583-588.

Sau, Samaresh, et al. “Multifunctional Nanoparticles for Cancer Immunotherapy: A Groundbreaking Approach for Reprogramming Malfunctioned Tumor Environment.” Journal of controlled release 274 (2018): 24–34.

Rizvi, Naiyer A. et al. “Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non–small Cell Lung Cancer.” Science (American Association for the Advancement of Science) 348.6230 (2015): 124–128.

Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8C T cell survival in HIV infection. J Exp Med. 2006, 203(10): 2281-2292.

Goubran, Hadi A. et al. “Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment.” Cancer Growth and Metastasis 2014.2014 (2014): 9–18.

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015; 125:3384-91.